Example: Heart Attack

Clinical Trials on Breast+Cancer

Total 9001 results

NCT04360330

Recruiting

SABER Study for Selected Early Stage Breast Cancer

Conditions: Breast Cancer; Early-stage Breast Cancer
NCT03721211

Withdrawn

Imaging With [11C]Martinostat in Breast Cancer

Conditions: Breast Cancer
NCT03863457

Active, not recruiting

[18F] F-GLN by PET/CT in Breast Cancer

Conditions: Breast Cancer
NCT03254875

Active, not recruiting

Rehabilitation After Breast Cancer

Conditions: Breast Cancer
NCT03641755

Recruiting

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Conditions: Breast Cancer
NCT03865654

Active, not recruiting

Individualizing Surveillance Mammography for Older Breast Cancer Survivors

Conditions: Breast Cancer
NCT03818087

Recruiting

Elevate! : An Elderly Breast Cancer Cohort Study

Conditions: Breast Cancer
NCT02956473

Recruiting

Supine MRI in Breast Cancer Patients Receiving Neoadjuvant Therapy

Conditions: Breast Cancer
NCT03596073

Recruiting

Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

Conditions: Breast Cancer
NCT03414684

Recruiting

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Conditions: Breast Cancer
NCT03473639

Recruiting

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

Conditions: Metastatic Breast Cancer; Breast Cancer
NCT03913936

Active, not recruiting

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot

Conditions: Breast Cancer
NCT03483012

Recruiting

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Conditions: Breast Cancer
NCT03316586

Active, not recruiting

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Conditions: Breast Cancer
NCT03289039

Recruiting

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Conditions: Breast Cancer
NCT03340402

Withdrawn

Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam Scanning

Conditions: Breast Cancer
NCT03375827

Active, not recruiting

Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer

Conditions: Breast Cancer
NCT02663973

Recruiting

Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III

Conditions: Breast Cancer
NCT03765983

Recruiting

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Conditions: Breast Cancer
NCT02926729

Recruiting

Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy

Conditions: Breast Cancer
NCT03598660

Not yet recruiting

Role of Sorcin and Annexin A3 in Breast Cancer Patients

Conditions: Breast Cancer
NCT03749421

Recruiting

Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer

Conditions: Breast Cancer
NCT03888677

Completed

Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer

Conditions: Breast Cancer
NCT04039230

Recruiting

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Conditions: Breast Cancer
NCT01224678

Completed

Vitamin D and Breast Cancer Biomarkers in Female Patients

Conditions: Breast Cancer
NCT02953860

Active, not recruiting

Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

Conditions: Breast Cancer
NCT03495115

Active, not recruiting

Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening

Conditions: Breast Cancer
NCT03990896

Recruiting

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Conditions: Breast Cancer
NCT02546232

Recruiting

Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting

Conditions: Breast Cancer
NCT01830933

Completed

Breast Cancer Risk Reduction: A Patient Doctor Intervention

Conditions: Breast Cancer
NCT03959891

Recruiting

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Conditions: Breast Cancer
NCT04033172

Recruiting

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Conditions: Breast Cancer; HER2-positive Breast Cancer
NCT03243331

Recruiting

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Conditions: Triple Negative Breast Cancer; Metastatic Breast Cancer
NCT02303145

Completed

Breast Cancer Survivorship & Work-Related Cognitive Limitation

Conditions: Breast Cancer
NCT02443428

Completed

Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry

Conditions: Breast Cancer
NCT01750164

Terminated

Patient Derived Breast Cancer Xenografts

Conditions: Metastatic Breast Cancer
NCT03051659

Active, not recruiting

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Conditions: Breast Cancer
NCT03447886

Completed

Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds

Conditions: Breast Cancer
NCT03887130

Completed

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Conditions: Breast Cancer
NCT02666079

Unknown status

The LightPath® Breast Cancer Study

Conditions: Breast Cancer
NCT03285412

Active, not recruiting

CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer

Conditions: Breast Cancer
NCT01320488

Suspended

Breast Cancer in Young Women: Is it Different?

Conditions: Female Breast Cancer
NCT01521676

Recruiting

Predictive Clinical and Biological Parameters in Breast Cancer

Conditions: Breast Cancer
NCT03183206

Completed

Safety and Efficiency of γδ T Cell Against Breast Cancer

Conditions: Breast Cancer
NCT03414658

Recruiting

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Conditions: Breast Cancer
NCT01434420

Unknown status

Triple Negative Breast Cancer: Study of Molecular and Genetic Factors

Conditions: Breast Cancer
NCT02637375

Withdrawn

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Conditions: Breast Cancer
NCT02999477

Recruiting

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Conditions: Breast Cancer
NCT01111175

Completed

Triple Negative Breast Cancer Biomarker Study

Conditions: Metastatic Breast Cancer; Triple Negative Breast Cancer
NCT04038489

Active, not recruiting

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer

Conditions: Breast Cancer; Estrogen Receptor-positive Breast Cancer

Clinical Trials on Breast+Cancer

Recent CRA jobs

Sr Programmer Analyst II - Europe

Manager, Strategic Feasibility

Sr Biostatistician II - Europe

Clin Data Team Lead

Clinical Data Associate

Clinical Research Associate (CRA Level I)- California

Clinical Research Associate (CRA Level I)- Pennsylvania

Clinical Trial Coordinator - Client-Dedicated - Northbrook, IL

Clinical Research Associate (CRA Level I)- Illinois

Clinical Research Associate (CRA Level I)- Texas